Premedication with an oral antioxidant cocktail before medical imaging exams could significantly reduce deoxyribonucleic acid (DNA) injury from the ionising radiation dose, finds new research presented at the Society of Interventional Radiology’s annual scientific meeting in Atlanta, USA.
Interventional News has learnt that interventional radiologists and urologists in France are teaming up to set up a multidisciplinary registry to collect data on prostatic artery embolization for the treatment of benign prostatic hyperplasia.
Endovascular treatment of intracranial aneurysm is effective in preventing long-term bleeding, but may be followed by aneurysm recurrences in a significant proportion of cases, according to a new magnetic resonance angiography (MRA) study published online in the journal Radiology.
Allium Medical has announced that it has received FDA clearance to market Gardia’s Wirion system in the United States for the carotid indication.
Following the results of SYMPLICITY HTN-3, which failed to show benefit of renal denervation in resistant hypertension patients, Medtronic announced in April the initiation of the SPYRAL HTN clinical trial programme, studying renal denervation in uncontrolled hypertension. Also in April, Boston Scientific announced the initiation of the REDUCE-HTN: REINFORCE, a randomised, sham-controlled study designed to demonstrate the effects of the Vessix renal denervation system by minimising variability and factors that may have affected results in SYMPLICITY HTN-3.
A combination of imaging systems from Siemens Healthcare is helping Southmead Hospital, Bristol, UK, to achieve its aim of becoming a leading provider of health services in Europe. With the hospital’s new £430m Brunel building offering pioneering treatment within state-of-the-art facilities, Siemens technology is increasing the speed of patient assessment and enabling elevated levels of patient throughput.
The Canadian Society for Vascular Surgery (CSVS) has released a list of specific tests, treatments or procedures that are commonly ordered but not always necessary in vascular surgery as part of the Choosing Wisely Canada campaign. The list identifies five targeted, evidence-based recommendations that can support conversations between patients and physicians about what care is really necessary.
For years, the radiology industry has focused on reducing, or eliminating patient exposure to radiation. Recently, the industry has shifted attention to the cumulative effect radiation exposure has over the course of a physician’s career.
Twelve-month data from the EXCITE ISR clinical trial were presented by Craig Walker at New Cardiovascular Horizons (NCVH; 27–29 May, New Orleans, USA). Results of the study show that Spectranetics’ laser atherectomy devices used with balloon angioplasty, are safer and more effective than angioplasty alone for treating femoropopliteal in-stent restenosis, demonstrating continued durability in 12-month results.
Presented for the first time at EuroPCR 2015 (19–22 May, Paris, France) during the “Hot line” session on peripheral interventions, new clinical data from two different studies show that the IN.PACT Admiral drug-coated balloon from Medtronic successfully treated long lesions in the superficial femoral and popliteal arteries.
Shockwave Medical has announced US$40m in funding, co-led by returning investor Sofinnova Partners and new investor Venrock, with the participation of RA Capital, Deerfield, Sectoral Asset Management, Ally - See more at: h
Silk Road Medical has announced that the company has received premarket approval (PMA) from the US Food & Drug Administration (FDA) for the Enroute transcarotid stent system. The Enroute transcarotid stent is the first carotid stent that is introduced and implanted into the carotid artery through a direct common carotid access point to enable a safe and more direct approach to carotid artery stenting.
Nitiloop has received FDA clearance for its first product, NovaCross, which is intended to be used in conjunction with a guidewire to access discrete regions of the coronary or peripheral vasculature.
The abstract, published by the American Society for Clinical Oncology (ASCO) as part of the 2015 annual meeting abstracts released on its website, reveals that Sirtex’s SIRFLOX study of 530 patients revealed median progression-free survival (PFS) in the liver of 20.5 months, an improvement of 7.9 months over the current standard chemotherapy plus Avastin.
In the past five years we have treated more than 400 patients for uterine fibroids, bone metastasis and osteoid osteoma in routine practice with significant clinical results and negligible adverse events, but therapeutic ultrasound still has some technological hurdles that need to be overcome, writes Alessandro Napoli.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos